Avenge Bio Announces Dosing of First Patient in Phase 1/2 Clinical Trial Evaluating AVB-001 for the Treatment of Ovarian Cancer by Carolyn Helms | Jan 9, 2023 | Portfolio News
Viridian Announces Positive Data from Ongoing Phase 1/2 Trial Evaluating Low Dose VRDN-001 in Patients with Thyroid Eye Disease (TED) by Carolyn Helms | Jan 8, 2023 | Portfolio News
Nalu Medical, Inc., Announces Publication of Two Spinal Cord Stimulation Clinical Studies by Carolyn Helms | Jan 5, 2023 | Portfolio News
Vaxcyte’s VAX-24 Granted FDA Breakthrough Therapy Designation for the Prevention of Invasive Pneumococcal Disease in Adults by Carolyn Helms | Jan 5, 2023 | Portfolio News
Theseus Pharmaceuticals Highlights Key Anticipated 2023 Milestones and Announces BCR-ABL as Target for Third Development Program by Carolyn Helms | Jan 5, 2023 | Portfolio News
